Ophthalmic treatment device manufacturer Nova Eye Medical has reported strong sales results following the US launch of its latest iTrack Advance glaucoma surgical device.
The iTrack Advance is a consumable device with an illuminated fibre optic tip designed to improve the efficacy of canaloplasty surgery in treating glaucoma.
The updated device was launched in May and can also be utilised by ophthalmologists, a large new market, as well as cataract surgeons.
US sales in the three months to 31 July were US$2.2 million, up 32 percent on the previous corresponding period.
Solid sales growth in the US is expected to continue, with a targeted programme of new customer acquisition to begin in late 2033.
Nova Eye Managing Director Tom Spurling said the company’s approach to the US market was providing promising early signs of growth.
Spurling said: “We will continue to reactivate inactive customer accounts before turning our focus to win new customer accounts in the remainder of the calendar year.
“In parallel, we will ramp up our manufacturing capabilities to meet this expected lift in sales demand.”
Spurling said the product launch at the American Society of Cataract and Refractive Surgery meeting provided significant sales momentum in June and July.
“Glaucoma consumable surgical devices represent the fastest growing market in opthalmology, of which the US represents the world’s largest market..
“Our best in class iTrack Advance device has been received well by US surgeons and we expect a continuation of solid sales growth we have so far achieved.”
Adelaide based Nova Eye has expanded its Fremont, California production base to materially increase production, including recruiting additional production operators.
Nova Eye Medical reports strong sales of glaucoma device
Browse @AuManufacturing’s coverage of Nova Eye Medical here